Chemistry

BOC Sciences's Videos

PROTACs are heterobifunctional molecules, which contain a small molecule targeting the protein of interest (warhead), a small molecule capable of recruiting an E3 ligase (E3 ligand), and a linker connecting the above two moieties.

PROTAC -BOC Sciences

BÜCHI Labortechnik AG

The Mini Spray Dryer S-300, based on 40 years of experience as a global market leader in laboratory spray drying, offers unique product design and unprecedented automation capabilities and smart features for a superior user experience. 

Benefit from:
-	Time-saving and flexibility: Use Auto Mode for a fully automated spray-drying process. Combine with remote-control possibilities, method programming and easy report generation for ultimate time savings and flexibility.  
-	Higher reproducibility: Better sample protection and smart system design features increase reproducibility. Automation and high process regulation of more parameters improve data, and full compatibility with previous generations of the spray dryer ensures reproducibility between systems
-	Smart design: Benefit from easy maintenance with convenient cyclone mounting and disassembly, coated cyclone increases yields and reproducibility, ruby-stone nozzle contributes to more stability, more flexibility due to second sample pump

👉 Find out more: https://bit.ly/3no2N7u

Product Launch of Revolutionary Lab Spray Dryer

Oncotarget

Oncotarget published this trending research paper on June 15, 2022 in Volume 13, entitled, "Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program" by researchers from Department of Medical Oncology, Hospital Virgen del Rocío, Sevilla, Spain; Department of Medical Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Department of Medical Oncology, Hospital Universitario A Coruña, A Coruña, Spain; Department of Medical Oncology, ICO Bellvitge, Hospitalet Llobregat, Barcelona, Spain; Department of Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain; Department of Medical Oncology, Hospital General Yague, Burgos, Spain; Department of Medical Oncology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain; Department of Medical Oncology, Hospital Marqués de Valdecilla, Santander, Spain; Department of Medical Oncology, Hospital Universitario Donostia, Donostia-San Sebastián, Spain; Department of Medical Oncology, Hospital Universitario Virgen Macarena, Sevilla, Spain; Department of Medical Oncology, Hospital Universitario La Princesa, Madrid, Spain; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Department of Medical Oncology, Complejo Asistencial Universitario de León, León, Spain; Roche Farma, S.A., Madrid, Spain; Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain.

DOI - https://doi.org/10.18632/oncotarget.28244

Correspondence to - Reyes Bernabé-Caro - reyesbernab@yahoo.es

Abstract

This retrospective observational study analyzed the clinical characteristics, treatment patterns and outcomes of 120 patients with advanced ALK-positive non-small-cell lung cancer (ALK+ NSCLC) according to data collected between November 2019 and October 2020 in 38 Spanish hospitals. Patients had progressed after 1–5 prior treatment lines (which included crizotinib in any prior line) and received subsequent therapy with alectinib in a local expanded access program. Median age was 58.7 years, 50% of patients were female, 64.1% had ECOG PS of 0–1, 85% presented stage IV, 95% had adenocarcinoma histology and 20.8% had brain metastases. After a median 9.6 months of alectinib treatment, objective response rate (ORR) was 54.5%, disease control rate (DCR) was 80%, median progression-free survival (PFS) was 9.4 months and median overall survival (OS) was 24.1 months. Patients with brain metastases achieved an intracranial DCR of 71.4%. Adverse events (AEs) were reported in 35.8% of patients (14.2% of AEs were grade ≥3). Over 40% of patients received some treatment after alectinib, most frequently lorlatinib (65.2%) and brigatinib (32.6%). This study provides information on real-world treatment patterns and confirms the tolerability and prolonged PFS and OS observed with alectinib in clinical trials, in unselected pretreated patients with advanced ALK+ NSCLC.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28244

Keywords - lung cancer, ALK-positive NSCLC, ALK inhibitor, crizotinib, alectinib, unselected patient

About Oncotarget

Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/OncotargetYouTube
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.com

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Trending With Impact: Real-World Treatment Patterns of Alectinib in Unselected Spanish ALK+ NSCLC Patients

Aging (Aging-US)

Aging (Aging-US) published this trending research research paper as the cover for Volume 14, Issue 11, entitled, “Histone deacetylase 4 reverses cellular senescence via DDIT4 in dermal fibroblasts” by researchers from the Department of Dermatology, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Republic of Korea; Institute of Human-Environment Interface Biology, Medical Research Center, Seoul National University, Seoul, Republic of Korea; Department of New Biology, DGIST, Daegu, Republic of Korea; Department of Biological Sciences, Seoul National University, Seoul, Republic of Korea; Institute on Aging, Seoul National University, Seoul, Republic of Korea.

DOI - https://doi.org/10.18632/aging.204118

Corresponding authors - Daehee Hwang - daehee@snu.ac.kr, Dong Hun Lee - ivymed27@snu.ac.kr, Jin Ho Chung - jhchung@snu.ac.kr

Abstract

Histone deacetylases (HDACs) remove acetyl groups from lysine chains on histones and other proteins and play a crucial role in epigenetic regulation and aging. Previously, we demonstrated that HDAC4 is consistently downregulated in aged and ultraviolet (UV)-irradiated human skin in vivo. Cellular senescence is a permanent cell cycle arrest induced by various stressors. To elucidate the potential role of HDAC4 in the regulation of cellular senescence and skin aging, we established oxidative stress- and UV-induced cellular senescence models using primary human dermal fibroblasts (HDFs). RNA sequencing after overexpression or knockdown of HDAC4 in primary HDFs identified candidate molecular targets of HDAC4. Integrative analyses of our current and public mRNA expression profiles identified DNA damage-inducible transcript 4 (DDIT4) as a critical senescence-associated factor regulated by HDAC4. Indeed, DDIT4 and HDAC4 expressions were downregulated during oxidative stress- and UV-induced senescence. HDAC4 overexpression rescued the senescence-induced decrease in DDIT4 and senescence phenotype, which were prevented by DDIT4 knockdown. In addition, DDIT4 overexpression reversed changes in senescence-associated secretory phenotypes and aging-related genes, suggesting that DDIT4 mediates the reversal of cellular senescence via HDAC4. Collectively, our results identify DDIT4 as a promising target regulated by HDAC4 associated with cellular senescence and epigenetic skin aging.

Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204118

Press release - https://www.aging-us.com/news_room/DDIT4-identified-as-candidate-target-of-HDAC4-associated-skin-aging

Keywords - aging, cellular senescence, DNA damage-inducible transcript 4, histone deacetylase 4, oxidative stress, ultraviolet light

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at http://www.Aging-US.com​​ and connect with us:

SoundCloud - https://soundcloud.com/Aging-Us
Facebook - https://www.facebook.com/AgingUS/
Twitter - https://twitter.com/AgingJrnl
Instagram - https://www.instagram.com/agingjrnl/
YouTube - https://www.youtube.com/agingus​
LinkedIn - https://www.linkedin.com/company/aging/
Pinterest - https://www.pinterest.com/AgingUS/

Aging-US is published by Impact Journals, LLC: http://www.ImpactJournals.com​​

Media Contact
18009220957
MEDIA@IMPACTJOURNALS.COM

Trending With Impact: DDIT4 as Candidate Target of HDAC4-Associated Skin Aging

Dennis Mangan from MTOR LLC in Bakersfield, California details his theory article published by Aging (Aging-US), entitled, “Iron: an underrated factor in aging.”

DOI - https://doi.org/10.18632/aging.203612

Corresponding author - Dennis Mangan - pdmangan@outlook.com

Abstract

Iron is an essential element for virtually all living organisms, but its reactivity also makes it potentially harmful. Iron accumulates with aging, and is associated with many age-related diseases; it also shortens the lifespans of several model organisms. Blocking iron absorption through drugs or natural products extends lifespan. Many life-extending interventions, such as rapamycin, calorie restriction, and old plasma dilution can be explained by the effects they have on iron absorption, excretion, and metabolism. Control of body iron stores so that they remain in a low normal range may be an important, lifespan- and healthspan-extending intervention.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.203612

Press release - https://www.aging-us.com/news_room/iron-an-underrated-factor-in-aging

Blog post - https://www.impactjournals.com/journals/blog/aging/trending-with-impact-is-iron-a-driver-of-aging/

Keywords - iron, aging, oxidative stress, calorie restriction, plasma dilution

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at http://www.Aging-US.com​​ or connect with us:

SoundCloud - https://soundcloud.com/Aging-Us
Facebook - https://www.facebook.com/AgingUS/
Twitter - https://twitter.com/AgingJrnl
Instagram - https://www.instagram.com/agingjrnl/
YouTube - https://www.youtube.com/agingus​
LinkedIn - https://www.linkedin.com/company/aging/
Pinterest - https://www.pinterest.com/AgingUS/

Aging-US is published by Impact Journals, LLC: http://www.ImpactJournals.com​​

Media Contact
18009220957
MEDIA@IMPACTJOURNALS.COM

Behind the Study: Iron: An Underrated Factor in Aging

Creative Enzymes

Enzyme labeling, also known as immunoenzymatic technology, is based on the immune reaction. It uses a highly specific immune reaction combined with the efficient catalytic action of enzymes to form a complete set of biological technologies that are highly specific and highly sensitive. https://www.creative-enzymes.com/service/Enzyme-Labelling-Services_358.html

Enzyme Labelling - Creative Enzymes

Creative Enzymes uses its expertise in enzyme manufacturing to supply customers enzymes using for life science research and production of medicines, food, alcohol, beer, fruit juice, fabric, paper, leather goods, etc. Our products are used worldwide in academic, commercial, and government laboratories in diverse applications, including basic research, drug discovery, cancer research, infectious disease research, microbiology, and personalized medicine. As a reliable supplier, Creative Enzymes supplies the products of high quality and competitive cost-effectiveness. We cooperate with a large number of satisfied customers in corresponding fields all over the world.  https://www.creative-enzymes.com/

Great Minds Choose Creative Enzymes

NIR technology offers the fastest method for quality control enabling you to make real-time decisions during processing of pharmaceutical, food and feed samples. In this concise webinar, cover:

✔️ Basic NIR theory
✔️ Key elements of NIR method development, including calibration development
✔️ Qualitative and quantitative application examples: identification of different sodium phosphates; identification of active ingredient topiramate in tablets; monitoring powder blend homogeneity

Learn more about NIR products: https://bit.ly/3Nt5780


Webinar: NIR for Real-Time Quality Control of Pharma and Food Samples

Oncotarget published this trending research paper on May 19, 2022 in Volume 13, entitled, "CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling" by researchers from the Center for Computation and Technology, Louisiana State University, Baton Rouge, LA; Department of Biological Sciences, Louisiana State University, Baton Rouge, LA; Division of Electrical and Computer Engineering, Louisiana State University, Baton Rouge, LA.

DOI - https://doi.org/10.18632/oncotarget.28234

Correspondence to - Michal Brylinski - michal@brylinski.org

Abstract

Development of novel anti-cancer treatments requires not only a comprehensive knowledge of cancer processes and drug mechanisms of action, but also the ability to accurately predict the response of various cancer cell lines to therapeutics. Numerous computational methods have been developed to address this issue, including algorithms employing supervised machine learning. Nonetheless, high prediction accuracies reported for many of these techniques may result from a significant overlap among training, validation, and testing sets, making existing predictors inapplicable to new data. To address these issues, we developed CancerOmicsNet, a graph neural network with sophisticated attention propagation mechanisms to predict the therapeutic effects of kinase inhibitors across various tumors. Emphasizing on the system-level complexity of cancer, CancerOmicsNet integrates multiple heterogeneous data, such as biological networks, genomics, inhibitor profiling, and gene-disease associations, into a unified graph structure. The performance of CancerOmicsNet, properly cross-validated at the tissue level, is 0.83 in terms of the area under the receiver operating characteristics, which is notably higher than those measured for other approaches. CancerOmicsNet generalizes well to unseen data, i.e., it can predict therapeutic effects across a variety of cancer cell lines and inhibitors. CancerOmicsNet is freely available to the academic community at https://github.com/pulimeng/CancerOmicsNet.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28234

Press release - https://www.oncotarget.com/news/pr/oncotarget-anti-cancer-drug-profiling-with-canceromicsnet/

Keywords - cancer growth rate, kinase inhibitors, differential gene expression, gene-disease association, cancer-specific networks

About Oncotarget

Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/OncotargetYouTube
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.com

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Chemistry

Refine By

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.